2-Methoxyestradiol Induces Mitotic Arrest, Apoptosis, and Synergistic Cytotoxicity with Arsenic Trioxide in Human Urothelial Carcinoma Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Kuo, Kuan Lin ^a   Lin, Wei Chou ^a   Ho, I Lin ^a   Chang, Hong Chiang ^a   Lee, Ping Yi ^a   Chung, Yuan Ting ^a   Hsieh, Ju Ton ^a   Pu, Yeong Shiau ^a   Shi, Chung Sheng ^b,c   Huang, Kuo How ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ARSENIC TRIOXIDE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DNA; HISTONE H2AX; HISTONE H3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN TYROSINE PHOSPHATASE; SERINE;

AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PROTEIN CLEAVAGE; TRANSITIONAL CELL CARCINOMA;

AGED; APOPTOSIS; ARSENICALS; BCL-ASSOCIATED DEATH PROTEIN; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; ESTRADIOL; FEMALE; HISTONES; HUMANS; MITOSIS; OXIDES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; UROLOGIC NEOPLASMS;

EID: 84881515058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068703     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer JClin 60: 277-300.
2. Cohen MH, Rothmann M, (2001) Gemcitabine and cisplatin for advanced, metastatic bladder cancer. JClinOncol 19: 1229-1231.
3. von der MH, Hansen SW, Roberts JT, Dogliotti L, Oliver T, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. JClinOncol 18: 3068-3077.
4. Latini DM, Lerner SP, Wade SW, Lee DW, Quale DZ, (2010) Bladder cancer detection, treatment and outcomes: opportunities and challenges. Urology 75: 334-339.
5. Lakhani NJ, Sarkar MA, Venitz J, Figg WD, (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23: 165-172.
6. Zhu BT, Conney AH, (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19: 1-27.
7. Verenich S, Gerk PM, (2010) Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm 7: 2030-2039.
8. Carothers AM, Hughes SA, Ortega D, Bertagnolli MM, (2002) 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett 187: 77-86.
9. Lee YM, Ting CM, Cheng YK, Fan TP, Wong RN, et al. (2008) Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells. Cancer Lett 268: 295-307.
10. Li DL, Zhang J, Zhang WJ, Pan L, Wang ZW, (2009) [Effects of 2-methoxyestradiol on the expression of caspase-3 and survivin in chronic myelocytic leukemia K562 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17: 335-339.
11. Li L, Bu S, Backstrom T, Landstrom M, Ulmsten U, et al. (2004) Induction of apoptosis and G2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res 24: 873-880.
12. Hou Y, Meyers CY, Akomeah M, (2009) A short, economical synthesis of 2-methoxyestradiol, an anticancer agent in clinical trials. J Org Chem 74: 6362-6364.
13. Kumar AP, Garcia GE, Orsborn J, Levin VA, Slaga TJ, (2003) 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 24: 209-216.
14. Lin HL, Liu TY, Wu CW, Chi CW, (2001) 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 92: 500-509.
15. Stander BA, Marais S, Vorster CJ, Joubert AM, (2010) In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line. J Steroid Biochem Mol Biol 119: 149-160.
16. Christian BJ, Loretz LJ, Oberley TD, Reznikoff CA, (1987) Characterization of human uroepithelial cells immortalized in vitro by simian virus 40. Cancer Res 47: 6066-6073.
17. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, et al. (1973) Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. International journal of cancer Journal international du cancer 11: 765-773.
18. Adachi M, Imai K, (2002) The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2. Cell death and differentiation 9: 1240-1247.
19. Huang KH, Kuo KL, Chen SC, Weng TI, Chuang YT, et al. (2012) Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PLoS One 7: e33615.
20. Hour TC, Pu YS, Lin CC, Huang SW, Chen J, et al. (2006) Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer. Anticancer research 26: 375-378.
21. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, et al. (2002) Cytotoxicity of arsenic trioxide to transitional carcinoma cells. Urology 60: 346-350.
22. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation 22: 27-55.
23. Woo RA, Jack MT, Xu Y, Burma S, Chen DJ, et al. (2002) DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J 21: 3000-3008.
24. Burlacu A, (2003) Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 7: 249-257.
25. Morgan DO, (1995) Principles of CDK regulation. Nature 374: 131-134.
26. Choi HJ, Zhu BT, (2012) Critical role of cyclin B1/Cdc2 up-regulation in the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiol. Biochim Biophys Acta 1823: 1306-1315.
27. Wei Y, Yu L, Bowen J, Gorovsky MA, Allis CD, (1999) Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 97: 99-109.
28. Chen CH, Lee WJ, Chang TC, Chen RJ, Chien CH, et al. (2009) Antiproliferative effects of 2-methoxyestradiol alone and in combination with chemotherapeutic agents on human endometrial cancer cells. Eur J Gynaecol Oncol 30: 275-280.
29. Mueck AO, Seeger H, (2010) 2-Methoxyestradiol-biology and mechanism of action. Steroids 75: 625-631.
30. Zoubine MN, Weston AP, Johnson DC, Campbell DR, Banerjee SK, (1999) 2-methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression. IntJOncol 15: 639-646.
31. Bonnet J, Mayonove P, Morris MC, (2008) Differential phosphorylation of Cdc25C phosphatase in mitosis. Biochem Biophys Res Commun 370: 483-488.
32. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer cell 3: 363-375.
33. Davoodpour P, Landstrom M, (2005) 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J Biol Chem 280: 14773-14779.
34. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P, (2003) Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101: 4098-4104.
35. Sanchez Y, Simon GP, Calvino E, de Blas E, Aller P, (2010) Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. The Journal of pharmacology and experimental therapeutics 335: 114-123.
36. Takahashi S, (2010) Combination therapy with arsenic trioxide for hematological malignancies. Anti-cancer agents in medicinal chemistry 10: 504-510.